Patients with inflammatory bowel disease (IBD) might be at increased risk for herpes zoster infection. We sought to quantify the risk of herpes zoster in patients with IBD and evaluate the effects of IBD and IBD medications on the risk of herpes zoster.
See editorial on page 1872; and related article on page 1928. I nflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC) are chronic inflammatory disorders involving the gastrointestinal tract of unknown etiology. The altered immune regulation seen in patients with IBD and medications used to treat IBD may predispose patients to systemic complications, such as an increased risk of infection. 1 Herpes zoster (HZ) results from reactivation of latent varicella zoster virus infection. 2 The clinical presentation is characterized by a painful, unilateral vesicular eruption and is often complicated by postherpetic neuralgia. 3 Previous studies observed that the risk of HZ is elevated by 1.2 to 1.8 times in patients with IBD as compared with patients without IBD, but these studies were either done before the advent of biologics, or excluded patients who were older than age 64. [4] [5] [6] Additionally, these prior studies have not assessed the validity of the codes used to identify HZ and also did not account for the impact of vaccination. They also did not take into consideration the severity of the disease or degree of steroid exposure.
To overcome these limitations and to evaluate the incidence and risk factors for HZ in a nationwide IBD population, we used a Veterans' Affairs (VA) cohort for our study. The VA has a predominantly older population, which makes it an ideal cohort to study HZ incidence in a high-risk population. 7 Unlike insurance databases, the VA database can be validated internally and vaccination records are documented. Our aims were to determine whether patients with IBD have an increased risk of HZ independent of immunosuppressive medication use and to quantify the extent that immunosuppression increases the risk while controlling for the disease activity.
Methods
We conducted 2 retrospective cohort studies among patients in the US national VA health care system using data from the VA Informatics and Computing Infrastructure from January 1, 2000, through June 30, 2016. We obtained inpatient and outpatient International Classification of Diseases, Version 9 and 10, Clinical Modification (ICD-9-CM, ICD-10-CM) diagnosis codes, encounters, procedures, pharmacy, and demographic data for the study population.
Study Population
The cohort study period was from January 1, 2000, through June 30, 2016. The study population included all veterans who had an ICD-9-CM or ICD-10-CM diagnosis for IBD during the study period. IBD was defined by the presence of an inpatient or outpatient diagnosis code of CD (556.xx), (K51.xx) and/or UC (555.xx), (K50.xx), respectively (Supplementary Table 1 ). We performed a validation of the algorithm based on IBD diagnostic codes. Two members of the investigative team (Y.S. and C.T.) manually reviewed the VA electronic medical records of 200 randomly selected patients who had any of the IBD diagnostic codes. The IBD diagnosis was confirmed in 189 out of 200 patients (94.5%) with 100% concordance between the 2 reviewers. To be included in the final cohort for this study the following criteria must have also been met: (1) 1 ICD-9 or ICD-10 diagnosis code for UC and/or CD, (2) 1 outpatient visit in VA health care system, (3) at least 1 outpatient pharmacy claim for any of the IBD medications in groups 1-5 ([1] 5-ASA only, [2] thiopurines, [3] anti-tumor necrosis factor [TNF] agents, [4] a combination of thiopurines and anti-TNF, and [5] vedolizumab), (4) at least 2 prescriptions of 1 distinct medication in medication groups 1-5, and (5) the censor date could not be preceded by the date of the first prescription of IBD medication/ pharmacy claim. For all patients, the follow-up began at the time of the start of the first IBD medication in any of the 5 medication groups and ended at the first of any following events: (1) incident HZ diagnosis, (2) HZ vaccination (ie, CPT code 90736), (3) death, or (4) last prescribed medication course for any of the 5 medication groups.
Cohort Study 1: Inflammatory Bowel Disease Versus Non-Inflammatory Bowel Disease Exposure The exposed group (n ¼ 13,001) in this cohort study consisted of those patients with IBD who were categorized in only medication group 1 (ie, 5-ASA) and without any exposure to corticosteroids. The unexposed group consisted of a cohort of randomly selected patients without IBD (n ¼ 35,510) from Corporate Data Warehouse who were matched with the exposed group at a ratio of up to 1:4 with respect to (1) Veterans Integrated Service Network number, which designates the geographic location of clusters of VA facilities in the same region; (2) year of first outpatient receipt of care in the VA; (3) age (at criteria 2 visit date); and (4) gender.
Outcome
The outcome was time to the first occurrence HZ in the follow-up period defined by relevant ICD-9-CM (053.xx), ICD-10-CM (B02.xx) codes for HZ and their complications (Supplementary Table 2 ). To validate the coding algorithm for HZ, 2 members of the investigative team (Y.S. and C.T.) performed manual review of the VA electronic medical records of 200 randomly selected patients who had any of the HZ diagnostic codes. HZ diagnosis was confirmed in 182 out of 200 patients (91%) with 100% concordance between the 2 reviewers.
Statistical Analyses
The baseline characteristics of the exposure groups were compared using descriptive statistics. Overall incidence rates of HZ in the respective comparison groups and in CD or UC subgroups were calculated as the number of events per 1000 patient-years. Multivariable Cox regression was used to estimate the hazard ratio (HR) and confidence interval (CI) for HZ risk associated with having IBD, UC, or CD and being exposed to 5-ASA versus not having IBD, adjusting for the geographic location; health care use defined as the number of patient visits (outpatient and inpatient); race; and the baseline comorbid medical conditions including hypertension (complicated/uncomplicated), diabetes, lymphoma, metastatic cancer, chronic pulmonary disease, congestive heart failure, renal failure, liver disease, and AIDS/ human immunodeficiency virus. Corporate Data Warehouse data was stored in Microsoft (Albuquerque, NM) SQL Server database and extracts were created from T-SQL coding using Microsoft SQL Server Management Studio. Final dataset creation and analysis were completed using SAS (Cary, NC) Enterprise Guide 7.1 software on SAS/Grid computing environment in SAS 9.4 intelligence platform. Analyses were also performed using R software version 3.3.1 (R Core Team [2016] . R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/).
Cohort Study 2: Inflammatory Bowel Disease By Medication Use
We conducted a second retrospective cohort study using the same national VA data in VA Informatics and Computing Infrastructure.
Exposure Groups
The exposure of interest was use of IBD medications categorized in 5 groups: (1) 5-ASA only, (2) thiopurines, (3) anti-TNF agents, (4) a combination of thiopurines and anti-TNF medications, and (5) vedolizumab (Supplementary Table 3 ). Medication use information was based on all inpatient and outpatient prescription records and related procedure codes. To determine exposure status to the medication groups on any given day during follow-up, a patient is considered to be exposed to a medication or medication combination in a given medication group starting from the first day of prescription. The patient continued in that medication group until the earliest of the following events: a medication from a higher-numbered medication group was prescribed, a 90-day gap was found between prescriptions, or until censoring. Regarding infusible medications, which included infliximab and vedolizumab, we included 3 months after the last CPT code entry as the period of exposure. A patient could also go back to a lower group if a medication was stopped and they were still on a medication from a lower group. Ninety-day gaps were considered as completion of a round of medication. A new round would start with the next prescription. The exposure was measured in a time-dependent manner. Specifically, the follow-up time for each patient was divided into consecutive 60-day intervals (except for the last interval, which could be <60 days). Within each interval, the exposure status was determined based on exposure to a medication group for any duration. In instances where medication group switches occurred during an interval, the exposure status was assigned according to the medication group associated with the longest duration during the interval.
Outcome
The outcome was time to incident HZ during the follow-up period among each medication group as defined previously.
Statistical Analyses
Demographic and clinical characteristics were summarized with counts and percentages for categorical variables, and mean (standard deviation) for continuous variables.
Overall incidence of HZ, the incidence by medication groups, and by age groups at the time of HZ diagnosis (<50, 50-60, and >60 years) within each medication group were estimated as the number of events per 1000 patient-years.
We performed Cox regression with time-dependent analysis to examine the risk of HZ by medication group. Medication group 5 (vedolizumab group) was excluded from the survival analyses because of its small sample size and no observed cases of HZ in this group. Specifically, we constructed multivariable Cox regression model with robust standard errors to estimate the aggregate HRs and 95% CIs by pooling the intervalspecific associations between the medication exposure group status at the beginning of each 60-day interval (ie, index date) and the risk of HZ during that interval. The model was adjusted for the following time-varying covariates updated in each interval: age at index date; intensity of prednisone use up to each index date (ie, total amount of prednisone taken from the beginning of follow-up divided by the total number of days up to the index date); and oral prednisone use within 30 days before index date, a proxy for disease flare up (ie, presence of any of the following events during a 60-day interval: a hospitalization, intravenous corticosteroid use, abdominal and or pelvic computed tomography, stool Clostridium difficile toxin testing). In addition, we also included the following fixed covariates: IBD diagnosis (UC/CD), geographic location (Midwest, North Atlantic, Pacific, Southeast, Continental), health care use (<6, 6-12, 13 visits/year), race (white, black, others, unknown), gender, and the baseline comorbid medical conditions. In ascertaining comorbidities, we used ICD-9-CM, ICD-10-CM code definitions developed by Elixhauser et al for use with administrative data. 8 We searched inpatient and outpatient diagnosis records 1 year before first medication date. An outpatient diagnosis was only kept if 2 distinct diagnosis records greater than 30 days apart were found. HRs between medication groups were estimated from this model along with 95% CIs.
Results
Cohort 1 (IBD vs non-IBD) included 13,001 eligible patients with IBD (42, 510 person-years of total follow-up) who had only been exposed to 5-ASA and 35,510 randomly selected matched patients without IBD (334,017 person-years of total follow-up) from VA Informatics and Computing Infrastructure. Table 1 presents the baseline characteristics of these 2 matched comparison groups. The overall crude incidence rate for HZ was 7.55 per 1000 person-years in the IBD group versus only 3.22 per 1000 person-years in the non-IBD Table 2) . Using CD as a control group, we found that patients with UC did not have statistically higher risk of HZ development (AHR, 1.16; 95% CI, 0.92-1.47). Table 3 shows HZ incidence rate in IBD and non-IBD groups stratified by age <50 years, 50-60 years, and >60 years. The IBD group had a higher incidence for HZ than the matched non-IBD group. In fact, the incidence of HZ among the youngest age group of patients with IBD (ie, 8.62 per 1000 person-years) exceeded that of the oldest group of control patients (ie, 3.3 per 1000 personyears).
Cohort 2 (IBD by medication use) included a total of 54,919 eligible patients with IBD who accumulated 243,506 person-years of at-risk time. During this followup period, 2007 total episodes of incident HZ were observed. A comparison of the patients who contributed at-risk time in each of the medication exposure groups with respect to total at-risk time, number of incident HZ episodes, crude HZ incident rate, and baseline characteristic is shown in Table 4 . Because of the time-varying nature of the exposure variable, a patient may contribute at-risk time in more than 1 medication groups. Of note, there were no incident HZ events in the vedolizumab group, which only included 167 patients. Therefore, vedolizumab group was dropped from the multivariable regression analysis.
In multivariable Cox regression analysis, compared with exposure to 5-ASA alone, exposure to thiopurines (AHR, 1.47; 95% CI, 1.31-1.65) or a combination of thiopurines and anti-TNF agents (AHR, 1.65; 95% CI, 1.22-2.23) was associated with increased risk of HZ. However, exposure to anti-TNF agents alone (AHR, 1.15; 95% CI, 0.96-1.38) was not associated with increased risk of HZ (Table 5 ). Both cumulative (AHR, 1.02; 95% CI, 1.01-1.03) and short-term (AHR, 1.27; 95% CI, 1.10-1.48) exposure to prednisone were associated with an increased risk of developing HZ. As expected, increased age (AHR, 1.01; 95% CI, 1.01-1.02) and disease flare (AHR, 3.69; 95% CI, 3.22-3.43) as described previously was also associated with an increased risk of developing HZ. Multivariate analysis of other risk factors for HZ development among patients with IBD is mentioned in Table 5 . Table 6 shows the absolute risk of HZ across the 4 medication groups stratified by age groups. There was a clear trend of increasing risk of HZ with rising age. However, patients in the younger age group (eg, <50) who were exposed to immunomodulators, anti-TNF, or a combination of these medications can have absolute risk of HZ comparable or higher than those older than age 60 in patients exposed to 5-ASA only.
Discussion
In this large nationwide VA cohort with patients with IBD, we analyzed the incidence and risk factors for HZ and the impact of IBD medications on them. We found that IBD itself without immunosuppressive medicine can predispose patients to develop HZ. Within the IBD cohort, older age, use of thiopurine or thiopurines and anti-TNF (combination therapy), IBD flare, higher cumulative prednisone use, or prednisone use within the last 30 days were independent risk factors for HZ incidence. In multivariate analysis, after controlling for multiple confounding factors including IBD flare, anti-TNF medicine use alone was not an independent risk factor for HZ in IBD. Patients with IBD who were <50 years of age and on combination therapy had a higher risk of HZ than those who were >60 years of age and on mesalamine therapy alone. The highest risk was observed among patients with IBD who were >60 years of age and on combination therapy, which approached w2% per year.
Patients with IBD have been previously shown to have an increased risk of HZ compared with general population in prior studies. [4] [5] [6] In our study, we compared patients with IBD who were only on mesalamine therapy with matched control group who had no IBD and we found that patients with both UC and CD have significantly higher chance of developing HZ. The incidence of HZ was slightly higher in patients with UC (7.98 per 1000 patient-years) compared with patients with CD (6.83 per 1000 patient-years) in our cohort but it was not statistically significant. This is in contrast with previous case-control studies that showed that patients with CD had higher risk of HZ than patients with UC. Unlike those studies, in our case-control analysis we excluded patients with IBD who were on prednisone and immunosuppressant medicines because we wanted to study the effect of the disease process in the absence of medication-induced systemic immunosuppression on HZ development. Our aim was to ascertain whether the immune dysregulation associated with IBD is in itself a factor that predisposes patients to an increased risk of HZ while removing the impact of known pharmacologic risk factors, such as corticosteroids, which have been extensively studied. Additionally, we censored our IBD cohort and non-IBD cohort for HZ vaccination, which other prior studies did not. Our result proposes that innate immune dysregulation in IBD itself may play an important role in HZ development.
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Because of higher risk of HZ in the IBD population, it is important to understand the HZ risk factors that predispose patients with IBD to develop HZ. In our cohort, use of thiopurine alone (AHR, 1.47; 95% CI, 1.31-1.65) and combination therapy (AHR, 1.65; 95% CI, 1.22-2.23) were independently associated with the increased risk of HZ after adjusting for other confounding factors. Previous studies that have evaluated the risk of HZ in IBD found a similar result of increased HZ risk with the use of thiopurine and combination therapy. [4] [5] [6] 9 Interestingly, the use of anti-TNF alone (AHR, 1.15; 95% CI, 0.96-1.38) was not an independent risk factor of HZ incidence after controlling for all possible confounding variables, most importantly for IBD flare. This is in contrast with existing literature, which states that anti-TNF use increases the risk of HZ incidence in IBD. [4] [5] [6] 9 However, none of these previous studies have evaluated IBD flare as one of the confounders, which could have overestimated the risk of HZ incidence in patients taking anti-TNF medicines. Although it is difficult to accurately capture all flares in a retrospective study we believe that the criteria we devised would capture most of the flares. As suspected, IBD flare had the strongest association with the development of HZ (HR, 3.69; 95% CI, 3.22-4.23). Further studies are warranted to support our findings.
Cumulative exposure of prednisone over the course of the disease and current use of prednisone could serve as a proxy of disease severity and be associated with increased HZ risk. While performing time-dependent analysis and including 2 additional time-dependent covariates designed to capture both chronic (ie, cumulative prednisone use per unit follow-up time) and current (ie, presence of events specific for IBD flare) disease activity, we found that intensity of cumulative prednisone exposure (HR, 1.02; 95% CI, 1.01-1.03) and prednisone use within 30 days of index date (HR, 1.27; 95% CI, 1.10-1.48) were both independent risk factors for HZ incidence after controlling for confounding factors. The result is in keeping with previous studies that have identified that longer duration and higher dose of glucocorticoids use confer a greater risk of HZ in IBD as demonstrated by Winthrop et al. 10 In addition to the use of immunosuppressive medicine, we found that advancing age (HR, 1.01; 95% CI, 1.01-1.02) is another independent risk factor for development of HZ in IBD population. A novel aspect of this study was the assessment of the combined effect of older age and medication use on HZ incidence in an IBD population. We found that patients with IBD who were >60 years of age and on combination therapy had the highest risk of HZ development, which approached almost 2% per year.
Advancement has been made in the field of vaccination against HZ. Recently a new recombinant subunit vaccine for HZ was developed by GlaxoSmithKline and in clinical trials it has shown 97.2% efficacy in patients >50 years of age.
11 Current American College of Gastroenterology guidelines have recommended vaccination among patients older than age 50 in patients with IBD.
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The high HZ rates observed in patients <50 years of age and on combination therapy or with immunomodulatory therapy in our study raises the question of whether younger patients with IBD should also be vaccinated for the prevention of HZ. Further studies should be conducted on universal vaccination among IBD population to assess the efficacy and feasibility of this new vaccination.
The major strength of this study was that data were captured from a nationwide cohort and had one of the longest follow-up durations spanning a 16-year period. Because we evaluated patients with IBD long after the advent of anti-TNF medicines, we were able to capture a large number of patients on anti-TNF and thiopurines unlike previous studies focused on the same hypothesis. [4] [5] [6] 9 The older population in the VA system also makes it an ideal cohort to study the incidence and risk factors for HZ in this high-risk group unlike one of the previous studies, which excluded patients who were >64 years of age. 5 HZ vaccination record is widely available in the VA system and ours was the first study that accounted for the use of Zostavax (Merck, Whitehouse Station, NJ). Additionally, we internally validated ICD-9 and ICD-10 codes for both IBD and HZ diagnosis. Our validation demonstrates that the diagnosis of HZ and IBD in our data is accurate with positive predictive value of 91% for HZ and 94.5% for IBD diagnosis. Another strength of our study is that we controlled for additional measure of disease activity/severity (cumulative prednisone exposure and prednisone exposure within 30 days and the first study to control for IBD flare), which helps minimize the effect of confounding by indication. Lastly, we used other surrogate measures as a mechanism for evaluating disease flare and controlled for this as well.
There are certain limitations in our study. The VA population is a selected cohort not only because of the male predominance but this is also an older population, and thus our results may not be generalizable to a general population. However, none of the previous studies have shown that gender is a risk factor for HZ infection in IBD population. Moreover, the size of the population still allowed us to perform meaningful age-specific subgroup analyses. Because we used the VA pharmacy database to estimate medication exposure rates, prescriptions filled outside the VA were not captured by our analysis. We do not anticipate this has created any bias because previous reports have shown that veterans have very good adherence in using the VA pharmacy. [13] [14] [15] We used a time-varying analytical approach and estimated the incidence of HZ risk for the respective medication groups based on the total person-time of exposure to a particular medication group and the number of HZ events that occurred during such person-time of exposure. Based on the known pharmacologic effects of the IBD medications, we expected that any impact of IBD medications on HZ risk would primarily be limited to the period of exposure to the respective medication groups. To the extent that this assumption might not precisely reflect the true induction periods between exposure to the various groups' IBD medications and HZ risk, our effect estimates could potentially contain some degree of error. A better understanding of the mechanisms mediating the effect of IBD medications on HZ risk would allow future studies to more accurately define the etiologically relevant exposure window and minimize such error.
Conclusions
Using a large nationwide VA database we found that IBD itself and treatment with thiopurines alone or in combination with anti-TNF agents, cumulative, and recent use of prednisone within 30 days were 
